Skip to main content
Clinical Trials/IRCT20210809052117N1
IRCT20210809052117N1
Not yet recruiting
Phase 3

Effect of Empagliflozin on clinical and echocardiographic parameters in non diabetic patient with reduced LVEF heart failure

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Shahid Beheshti University of Medical Sciences
Enrollment
44
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age: 18 yr\_80 yr
  • Heart failure with reduced EF \<40%
  • Nondiabetic
  • Stable symptom and therapy for heart failure

Exclusion Criteria

  • Cardiovascular event, admission for cardiovascular or renal complications within last 3 months
  • Cancer or life\-threatening condition
  • Estimated GFR \< 45 ml/min/m2
  • Systolic blood pressure \< 90mmhg
  • Pregnancy or lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Impact of Empagliflozin on heart in patients with myocardial infarctioMyocardial infarctionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2016-004591-22-ATMedical University of Graz/Department of Internal Medicine/Division of Endocrinology and Diabetology476
Not yet recruiting
Phase 2
Efficacy of Empagliflozin on cardiac function in non- diabetic patients after primary percutaneous angioplasty on left anterior descending coronary arteryacute myocardial infarction.121-09
IRCT20200727048226N1Tehran University of Medical Sciences88
Active, not recruiting
Phase 1
Effects of empagliflozin on cardiac remodeling and myocardial sympathetic nervous system in diabetic patients affected by chronic heart failurediabetes mellitus and heart failureMedDRA version: 20.0Level: LLTClassification code 10011949Term: Decompensation cardiacSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2019-002202-43-ITAOU FEDERICO II34
Not yet recruiting
Phase 4
To Study the effect of Empagliflozin on the cardiovascular biomarkers in diabetic patients myocardial infarctioCondition 1: Myocardial Infarction. Condition 2: Type 2 diabetes.Acute transmural myocardial infarction of unspecified siteType 2 diabetes mellitus without complicationsI21.3E11.9
IRCT20230724058910N1Zanjan University of Medical Sciences60
Recruiting
Phase 2
The effect of Empagliflozin on left ventricular ejection fraction in non-diabetic patients with acute anterior ST elevation Myocardial infarction treated with primary PCIAcute anterior ST elevation Myocardial infarction treated with primary PCI.ST elevation (STEMI) myocardial infarction of anterior wallI21.0
IRCT20221227056950N1Mashhad University of Medical Sciences64